Characteristics of reported immune-related AEs following nivolumab combination therapy

In this supplemental table, we report the characteristics of immune-related adverse events following nivolumab combination therapy as organized by system class. This is a supplemental file with the original manuscript as published in the Journal of the American Academy of Dermatology "Evaluating immune-related adverse events associated with the novel LAG3 inhibitor relatlimab in combination treatment of malignant melanoma: A retrospective comparative pharmacovigilance analysis of the FAERS database".